The growing reliance on blood tests to detect Alzheimer's disease may need to account for significant biological differences between men and women, potentially reshaping how clinicians interpret these emerging diagnostic tools. While universal cutoff values might suffice for basic screening, the nuanced patterns revealed could influence treatment timing and clinical trial enrollment strategies.
Analysis of plasma biomarkers from the Alzheimer's Disease Neuroimaging Initiative revealed distinct sex-based differences across multiple disease indicators. Among cognitively healthy individuals, men showed lower levels of amyloid beta-42 and glial fibrillary acidic protein (GFAP), while displaying higher phosphorylated tau-217 to amyloid ratios. In those already experiencing cognitive decline, women demonstrated elevated GFAP, p-tau217, and p-tau217/amyloid ratios compared to their male counterparts. Most striking was the finding that p-tau217 markers predicted cognitive decline only in women without existing impairment.
These findings illuminate a critical gap in precision medicine approaches to neurodegeneration. While women face higher lifetime Alzheimer's risk, blood-based biomarker research has largely overlooked sex-specific patterns. The differential predictive power observed suggests that identical biomarker levels may carry different prognostic weight depending on biological sex. This has immediate implications for clinical trial design, where enrichment strategies typically rely on biomarker thresholds to identify at-risk participants. The research indicates that applying uniform criteria across sexes might inadvertently skew participant selection, potentially affecting trial outcomes and generalizability. As blood-based Alzheimer's testing moves toward clinical implementation, incorporating these sex-specific patterns could enhance diagnostic accuracy and ensure equitable healthcare outcomes for both men and women facing cognitive decline.